MolMed S.p.A.. (11/14/17). "Press Release: MolMed Completed the Fourth Tranche of the Share Capital Increase to Be Reserved to Société Générale Pursuant to “SEF – Standby Equity Facility” Agreement [Not for United States of America, Australia, Canada or

	Organisation	MolMed S.p.A. (MLMD.MI)
	Group	Asahi Glass (AGC) (Group)
	Organisation 2	Société Générale S.A.
	Group	Société Générale (Group)
	Product	investment banking
	Product 2	cancer drug
	Person	Palmisano, Riccardo (InnovaVector 202210– before MolMed 201606 CEO)

Not for distribution, directly or indirectly, in the United States of America, Australia, Canada or Japan

Following the press release disclosed to the market on 13 November 2017, MolMed S.p.A. (MLM.MI) (“MolMed” or the “Company”) announces the settlement of the fourth tranche (the “Fourth Tranche”) of the share capital increase against payment, in one or more tranches, in divisible form, to be executed by and no later than 31 October 2018, without pre-emptive rights pursuant to Article 2441, fourth paragraph, second sentence of the Italian Civil Code reserved to Société Générale (“SG”) pursuant to the agreement named “SEF – Standby Equity Facility” executed on 6 October 2016 between the Company and SG (the “SEF Agreement”). The name “SEF – Standby Equity Facility” is an exclusive trade name of SG.

Pursuant to the SEF Agreement and in respect of the Fourth Tranche, SG has undertaken to subscribe no. 12,000,000 MolMed ordinary shares, equal to 2.63% of the Company’s share capital, at a price equal to Euro 0.4411 per share (of which Euro 0.0471 represents capital and the remainder represents share premium), for a total amount of Euro 5,293,200.00.

Therefore, the Company has issued today No. 12,000,000 ordinary shares against payment of the relevant consideration by SG.

The new share capital of MolMed will be equal to Euro 21,514,284.36 divided into no. 456,962,393 ordinary shares with no par value.

The execution of the SEF Agreement will enable the Company to find resources, by benefiting from the flexibility of such tool, to satisfy the Company’s periodic liquidity needs, as well as to contribute to the development of the industrial plans, over the term of 24 months of the SEF Agreement.

Pursuant to the SEF Agreement, SG is not subject to any lock-up on the Shares and the Company has not executed any agreement with SG for the resale of such Shares on the market. No stock lending agreement or guarantee on the Shares is in place between SG and the Company.

The Shares issued in relation to the Fourth Tranche, together with any ordinary shares issued in the 12 months preceding the date of the utilization request, do not exceed 10% of MolMed’s ordinary shares already admitted to trading on the Italian Stock Exchange on the date of the relevant Utilization Request and, therefore, the Fourth Tranche of the Share Capital Increase is exempt from the obligation to publish a listing prospectus, pursuant to Article 57, paragraph 1, let. a) of the regulation approved by CONSOB resolution no. 11971/1999.

-----------------------
This press release is written in compliance with public disclosure obligations established by Consob’s (Italian securities & exchange commission) Issuers Regulation.
-----------------------

About MolMed

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed’s pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression prophylaxis, currently in Phase III in high-risk acute leukaemia and granted a Conditional Marketing Authorisation by the European Commission; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass, currently investigated in a broad clinical programme, involving more than 1000 treated patients; CARCD44v6 is an immune gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to market, including scale-up and cGMP manufacturing of viral vectors and patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and an operating unit at OpenZone in Bresso (Milan, Italy). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).

For further information:

Riccardo Palmisano
Investor Relations & Communication Director – ad interim
MolMed S.p.A.
phone: +39 02 212771
fax: +39 02 21277.325
e-mail: investor.relations@molmed.com

Andrea Quaglino
Administration, Finance & Control Director
MolMed S.p.A.
phone: +39 02 21277.302
fax: +39 02 21277.404
e-mail: afc@molmed.com

Press agent
Federico Ferrari
SEC Relazioni Pubbliche e Istituzionali s.r.l.
phone: +39 02 6249991 – mobile +39 347 6456873
e-mail: ferrari@secrp.it

MOLMED S.p.A. Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325 info@molmed.com - www.molmed.com Share capital € 20,949,084.36 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159 1

Record changed: 2023-06-05